Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subhashis Banerjee

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
World Neurosurgery|September 28, 2015
Design and Validation of an Open-Source, Partial Task Trainer for Endonasal Neuro-Endoscopic Skills Development: Indian ExperienceRamandeep Singh, Britty Baby, Natesan Damodaran, et al.
Neurosurgery|January 14, 2015
Quantitative analysis of variable extent of anterior clinoidectomy with intradural and extradural approaches: 3-dimensional analysis and cadaver dissectionManjul Tripathi, Rama Chandra Deo, Natesan Damodaran, et al.
The British Journal of Dermatology|January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trialsMark Lebwohl, Richard B Warren, Howard Sofen, et al.
European Radiology|August 12, 2024
Simulation training in mammography with AI-generated images: a multireader studyKrithika Rangarajan, Veeramakali Vignesh Manivannan, Harpinder Singh, et al.
Circulation|October 11, 2019
Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and HypertensionJun Peng, Wanpen Vongpatanasin, Anastasia Sacharidou, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Journal of the American Academy of Dermatology|July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summaryApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
World Neurosurgery|September 28, 2015
Design and Validation of an Open-Source, Partial Task Trainer for Endonasal Neuro-Endoscopic Skills Development: Indian ExperienceRamandeep Singh, Britty Baby, Natesan Damodaran, et al.
Neurosurgery|January 14, 2015
Quantitative analysis of variable extent of anterior clinoidectomy with intradural and extradural approaches: 3-dimensional analysis and cadaver dissectionManjul Tripathi, Rama Chandra Deo, Natesan Damodaran, et al.
The British Journal of Dermatology|January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trialsMark Lebwohl, Richard B Warren, Howard Sofen, et al.
European Radiology|August 12, 2024
Simulation training in mammography with AI-generated images: a multireader studyKrithika Rangarajan, Veeramakali Vignesh Manivannan, Harpinder Singh, et al.
Circulation|October 11, 2019
Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and HypertensionJun Peng, Wanpen Vongpatanasin, Anastasia Sacharidou, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Journal of the American Academy of Dermatology|July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summaryApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Pageof 12